Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “buy” rating reaffirmed by research analysts at Leerink Swann in a report released on Friday. They currently have a $15.00 price target on the stock. Leerink Swann’s target price indicates a potential upside of 188.46% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, November 10th. Bank of America Corp. cut shares of Adaptimmune Therapeutics PLC from a “neutral” rating to an “underperform” rating in a research report on Monday, October 24th. Finally, Raymond James Financial Inc. assumed coverage on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 30th. They set an “outperform” rating and a $16.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $14.35.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 5.20 on Friday. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $12.85. The firm’s market cap is $368.08 million. The firm’s 50-day moving average price is $5.55 and its 200-day moving average price is $7.68.

Institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock valued at $888,000 after buying an additional 3,519 shares during the last quarter. Polar Capital LLP boosted its position in shares of Adaptimmune Therapeutics PLC by 20.0% in the third quarter. Polar Capital LLP now owns 60,000 shares of the company’s stock valued at $423,000 after buying an additional 10,000 shares during the last quarter. Glenmede Trust Co. NA boosted its position in shares of Adaptimmune Therapeutics PLC by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock valued at $170,000 after buying an additional 17,823 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Adaptimmune Therapeutics PLC during the third quarter valued at $149,000. Finally, Springbok Capital Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at $202,000. 44.36% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.